J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
Long-term efficacy and safety in the resonate study: ibrutinib in patients with previously treated chronic lymphocytic leukemia (cll) with up to four years follow-up
Marco Montillo,John C. Byrd,Peter Hillmen,Susan O'Brien,Jaqueline C. Barrientos,N.M. Reddy,S. E. Coutre,Constantine S. Tam,Stephen P. Mulligan,Ulrich Jaeger,Paul M. Barr,Richard R. Furman,Thomas J. Kipps,Patrick Thornton,Carol Moreno,John M. Pagel,Jan A. Burger,Jeffrey A. Jones,S. Dai,R. Vezan,D.F. James,Jennifer R. Brown +21 more
TL;DR: BGB‐3111 is well tolerated and highly active in R/R and TN CLL/SLL and included in expansion cohorts at the recommended phase 2 dose.
Journal ArticleDOI
Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)
Veronica A Guerra,Jan A. Burger,Gautam Borthakur,Elias Jabbour,Naveen Pemmaraju,Tapan M. Kadia,Guillermo Garcia-Manero,Hagop M. Kantarjian,Marina Konopleva,Courtney D. DiNardo +9 more
TL;DR: This study evaluated safety and efficacy of the oral glutaminase inhibitor CB-839 in combination with azacitidine in MDS with high-risk genomic features including TP53, ASXL1, EZH2, or RUNX1 mutations.
Journal ArticleDOI
Ibrutinib Can Modulate the T Cell Response in Chronic Lymphocytic Leukemia By Reducing PD1/PDL1 Interactions
Kayo Kondo,Jan A. Burger,Keating Micheal,Jamie Tran,Muharrem Muftuoglu,May Daher,Hila Shaim,Philip A. Thompson,Nobuhiko Imahashi,Abdullah Alsuliman,William G. Wierda,Enli Liu,Elizabeth J. Shpall,Katayoun Rezvani +13 more
TL;DR: It is proposed that ibrutinib therapy can modulate the T cell response through multiple mechanisms which include (i) direct inhibition of ITK and skewing of the Tcell response toward a Th1 profile; (ii) reduction in PD1/PDL1 expression on B and T cells and (iii). suppression of Tregs.
Journal ArticleDOI
High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome.
Preetesh Jain,Michael J. Keating,Phillip Thompson,Long Trinh,Xuemei Wang,William G. Wierda,Alessandra Ferrajoli,Jan A. Burger,Hagop M. Kantarjian,Zeev Estrov,Lynne V. Abruzzo,Susan O'Brien +11 more
TL;DR: Patients with previously untreated chronic lymphocytic leukemia with del11q fluorescence in situ hybridization (FISH) abnormality had significantly shorter OS and TTFT as compared with patients with low FISH%, particularly in sole del 11q; this negative impact of high FISH% of del11Q on OS andTTFT was diminished with coexistent del13q.
Journal ArticleDOI
Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome- Outcome in Previously Untreated Patients.
Gautam Borthakur,Guillermo Garcia-Manero,Zeev Estrov,Marina Konopleva,Jan A. Burger,Deborah A. Thomas,Tapan M. Kadia,Betsy Williams,Solly George,Hagop M. Kantarjian +9 more
TL;DR: The efficacy and safety of the combination of GO with decitabine, another hypomethylating agent in AML and myelodysplastic sydromes (MDS) is investigated, with 33 patients with previously untreated AML or MDS enrolled in the trial.